582 related articles for article (PubMed ID: 31082799)
1. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
Kalavalapalli S; Bril F; Guingab J; Vergara A; Garrett TJ; Sunny NE; Cusi K
J Endocrinol; 2019 Jun; 241(3):293-305. PubMed ID: 31082799
[TBL] [Abstract][Full Text] [Related]
2. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity.
Patterson RE; Kalavalapalli S; Williams CM; Nautiyal M; Mathew JT; Martinez J; Reinhard MK; McDougall DJ; Rocca JR; Yost RA; Cusi K; Garrett TJ; Sunny NE
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E484-94. PubMed ID: 26814015
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.
Kalavalapalli S; Bril F; Koelmel JP; Abdo K; Guingab J; Andrews P; Li WY; Jose D; Yost RA; Frye RF; Garrett TJ; Cusi K; Sunny NE
Am J Physiol Endocrinol Metab; 2018 Aug; 315(2):E163-E173. PubMed ID: 29634314
[TBL] [Abstract][Full Text] [Related]
4. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
[TBL] [Abstract][Full Text] [Related]
5. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122.
Chai C; Cox B; Yaish D; Gross D; Rosenberg N; Amblard F; Shemuelian Z; Gefen M; Korach A; Tirosh O; Lanton T; Link H; Tam J; Permyakova A; Ozhan G; Citrin J; Liao H; Tannous M; Hahn M; Axelrod J; Arretxe E; Alonso C; Martinez-Arranz I; Betés PO; Safadi R; Salhab A; Amer J; Tber Z; Mengshetti S; Giladi H; Schinazi RF; Galun E
Gastroenterology; 2020 Sep; 159(3):999-1014.e9. PubMed ID: 32450149
[TBL] [Abstract][Full Text] [Related]
6. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
Camastra S; Astiarraga B; Tura A; Frascerra S; Ciociaro D; Mari A; Gastaldelli A; Ferrannini E
Diabetes Obes Metab; 2017 Mar; 19(3):412-420. PubMed ID: 27898183
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance is mechanistically linked to hepatic mitochondrial remodeling in non-alcoholic fatty liver disease.
Shannon CE; Ragavan M; Palavicini JP; Fourcaudot M; Bakewell TM; Valdez IA; Ayala I; Jin ES; Madesh M; Han X; Merritt ME; Norton L
Mol Metab; 2021 Mar; 45():101154. PubMed ID: 33359401
[TBL] [Abstract][Full Text] [Related]
9. C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis.
Rahman K; Liu Y; Kumar P; Smith T; Thorn NE; Farris AB; Anania FA
Lab Invest; 2016 Aug; 96(8):895-908. PubMed ID: 27239734
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
13. Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.
Cai X; Fang C; Hayashi S; Hao S; Zhao M; Tsutsui H; Nishiguchi S; Sheng J
J Gastroenterol; 2016 Aug; 51(8):819-29. PubMed ID: 26794005
[TBL] [Abstract][Full Text] [Related]
14. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
Finn PD; Rodriguez D; Kohler J; Jiang Z; Wan S; Blanco E; King AJ; Chen T; Bell N; Dragoli D; Jacobs JW; Jain R; Leadbetter M; Siegel M; Carreras CW; Koo-McCoy S; Shaw K; Le C; Vanegas S; Hsu IH; Kozuka K; Okamoto K; Caldwell JS; Lewis JG
Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G412-G424. PubMed ID: 30605011
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
Trevaskis JL; Griffin PS; Wittmer C; Neuschwander-Tetri BA; Brunt EM; Dolman CS; Erickson MR; Napora J; Parkes DG; Roth JD
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G762-72. PubMed ID: 22268099
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Armstrong MJ; Hull D; Guo K; Barton D; Hazlehurst JM; Gathercole LL; Nasiri M; Yu J; Gough SC; Newsome PN; Tomlinson JW
J Hepatol; 2016 Feb; 64(2):399-408. PubMed ID: 26394161
[TBL] [Abstract][Full Text] [Related]
18. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
[TBL] [Abstract][Full Text] [Related]
19. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease.
Sunny NE; Kalavalapalli S; Bril F; Garrett TJ; Nautiyal M; Mathew JT; Williams CM; Cusi K
Am J Physiol Endocrinol Metab; 2015 Aug; 309(4):E311-9. PubMed ID: 26058864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
